Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab in Systemic Lupus Erythematosus
NCT05155345Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of mosunetuzumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Roche. Primary endpoint: Percentage of participants with adverse events at 12 months. Started Jan 2022; status: completed.
02
Drugs
mosunetuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05155345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155345.